https://www.biopharmawatch.com/news/SMMT/ivonescimab-monotherapy-significant-benefit-pembrolizumab BiopharmaWatch en 2026-09-13T11:00:00.000Z Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China https://www.biopharmawatch.com/news/BETR/betterlife-pharma-us100-million-public-offering BiopharmaWatch en 2026-09-11T23:45:00.000Z BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants https://www.biopharmawatch.com/news/MRBK/meridian-corporation-fiduciary-duties-investigation BiopharmaWatch en 2026-09-11T22:48:00.000Z SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Meridian Corporation (NASDAQ: MRBK). https://www.biopharmawatch.com/news/SRRK/fda-approval-isembyld-apitegromab-sma BiopharmaWatch en 2026-09-11T22:25:00.000Z Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA) https://www.biopharmawatch.com/news/ENBI.X/entheon-adopts-semi-annual-reporting BiopharmaWatch en 2026-09-11T22:18:00.000Z Entheon Adopts Semi-Annual Reporting